{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:11:36Z","timestamp":1766869896445,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG064149"],"award-info":[{"award-number":["AG064149"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00213-024-06525-9","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T12:02:33Z","timestamp":1704888153000},"page":"975-986","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination strategy employing BACE1 inhibitor and memantine to boost cognitive benefits in Alzheimer\u2019s disease therapy"],"prefix":"10.1007","volume":"241","author":[{"given":"Abu Md Mamun","family":"Tarif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasi","family":"Huhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-8212","authenticated-orcid":false,"given":"Masuo","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"6525_CR1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1021\/acschemneuro.7b00270","volume":"8","author":"S Alam","year":"2017","unstructured":"Alam S, Lingenfelter KS, Bender AM, Lindsley CW (2017) Classics in chemical neuroscience: memantine. ACS Chem Neurosci 8:1823\u20131829","journal-title":"ACS Chem Neurosci"},{"key":"6525_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367:795\u2013804","journal-title":"N Engl J Med"},{"key":"6525_CR3","doi-asserted-by":"publisher","first-page":"8823","DOI":"10.3390\/molecules27248823","volume":"27","author":"FH Bazzari","year":"2022","unstructured":"Bazzari FH, Bazzari AH (2022) BACE1 inhibitors for Alzheimer\u2019s disease: the past, present and any future? Molecules 27:8823","journal-title":"Molecules"},{"key":"6525_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fnagi.2018.00229","volume":"10","author":"T Blume","year":"2018","unstructured":"Blume T, Filser S, Jaworska A, Blain JF, Koenig G, Moschke K, Lichtenthaler SF, Herms J (2018) BACE1 inhibitor MK-8931 alters formation but not stability of dendritic spines. Front Aging Neurosci 10:229","journal-title":"Front Aging Neurosci"},{"key":"6525_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1096\/fj.10-167213","volume":"25","author":"WP Chang","year":"2011","unstructured":"Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J (2011) \u03b2-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 25:775\u2013784","journal-title":"FASEB J"},{"key":"6525_CR6","doi-asserted-by":"publisher","first-page":"13ra11","DOI":"10.1126\/scitranslmed.3000337","volume":"2","author":"VW Chow","year":"2010","unstructured":"Chow VW, Savonenko AV, Melnikova T, Kim H, Price DL, Li T, Wong PC (2010) Modeling an anti-amyloid combination therapy for Alzheimer\u2019s disease. Sci Transl Med 2:13ra11","journal-title":"Sci Transl Med"},{"key":"6525_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nprot.2006.170","volume":"1","author":"RM Deacon","year":"2006","unstructured":"Deacon RM (2006) Assessing nest building in mice. Nat Protoc 1:1117\u20131119","journal-title":"Nat Protoc"},{"key":"6525_CR8","doi-asserted-by":"publisher","first-page":"e12974","DOI":"10.1371\/journal.pone.0012974","volume":"5","author":"L Devi","year":"2010","unstructured":"Devi L, Ohno M (2010) Phospho-eIF2\u03b1 level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. PLoS One 5:e12974","journal-title":"PLoS One"},{"key":"6525_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.nbd.2011.09.001","volume":"45","author":"L Devi","year":"2012","unstructured":"Devi L, Ohno M (2012) Mitochondrial dysfunction and accumulation of the \u03b2-secretase-cleaved C-terminal fragment of APP in Alzheimer\u2019s disease transgenic mice. Neurobiol Dis 45:417\u2013424","journal-title":"Neurobiol Dis"},{"key":"6525_CR10","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1038\/tp.2013.59","volume":"3","author":"L Devi","year":"2013","unstructured":"Devi L, Ohno M (2013) Mechanisms that lessen benefits of \u03b2-secretase reduction in a mouse model of Alzheimer\u2019s disease. Transl Psychiatry 3:e284","journal-title":"Transl Psychiatry"},{"key":"6525_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.55","volume":"5","author":"L Devi","year":"2015","unstructured":"Devi L, Ohno M (2015a) TrkB reduction exacerbates Alzheimer\u2019s disease-like signaling aberrations and memory deficits without affecting \u03b2-amyloidosis in 5XFAD mice. Transl Psychiatry 5:e562","journal-title":"Transl Psychiatry"},{"key":"6525_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13041-015-0110-5","volume":"8","author":"L Devi","year":"2015","unstructured":"Devi L, Ohno M (2015b) A combination Alzheimer\u2019s therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice. Mol Brain 8:19","journal-title":"Mol Brain"},{"key":"6525_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pbb.2016.03.002","volume":"144","author":"L Devi","year":"2016","unstructured":"Devi L, Ohno M (2016) Cognitive benefits of memantine in Alzheimer\u2019s 5XFAD model mice decline during advanced disease stages. Pharmacol Biochem Behav 144:60\u201366","journal-title":"Pharmacol Biochem Behav"},{"key":"6525_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1567205012666141218125042","volume":"12","author":"L Devi","year":"2015","unstructured":"Devi L, Tang J, Ohno M (2015) Beneficial effects of the \u03b2-secretase inhibitor GRL-8234 in 5XFAD Alzheimer\u2019s transgenic mice lessen during disease progression. Curr Alzheimer Res 12:13\u201321","journal-title":"Curr Alzheimer Res"},{"key":"6525_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-005-2230-6","volume":"181","author":"H Dong","year":"2005","unstructured":"Dong H, Csernansky CA, Martin MV, Bertchume A, Vallera D, Csernansky JG (2005) Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer\u2019s disease. Psychopharmacology 181:145\u2013152","journal-title":"Psychopharmacology"},{"key":"6525_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.nlm.2011.08.003","volume":"96","author":"ST Ferreira","year":"2011","unstructured":"Ferreira ST, Klein WL (2011) The A\u03b2 oligomer hypothesis for synapse failure and memory loss in Alzheimer\u2019s disease. Neurobiol Learn Mem 96:529\u2013543","journal-title":"Neurobiol Learn Mem"},{"key":"6525_CR17","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.1523\/JNEUROSCI.0482-13.2013","volume":"33","author":"CP Figueiredo","year":"2013","unstructured":"Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, De Felice FG, Ferreira ST (2013) Memantine rescues transient cognitive impairment caused by high-molecular-weight A\u03b2 oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci 33:9626\u20139634","journal-title":"J Neurosci"},{"key":"6525_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.biopsych.2014.10.013","volume":"77","author":"S Filser","year":"2015","unstructured":"Filser S, Ovsepian SV, Masana M, Blazquez-Llorca L, Brandt Elvang A, Volbracht C, Muller MB, Jung CK, Herms J (2015) Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol Psychiatry 77:729\u2013739","journal-title":"Biol Psychiatry"},{"key":"6525_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-170672","volume":"62","author":"J Folch","year":"2018","unstructured":"Folch J, Busquets O, Ettcheto M, S\u00e1nchez-L\u00f3pez E, Castro-Torres RD, Verdaguer E, Garcia ML, Olloquequi J, Casades\u00fas G, Beas-Zarate C, Pelegri C, Vilaplana J, Auladell C, Camins A (2018) Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimers Dis 62:1223\u20131240","journal-title":"J Alzheimers Dis"},{"key":"6525_CR20","volume-title":"The mouse brain in stereotaxic coordinates","author":"KBJ Franklin","year":"2008","unstructured":"Franklin KBJ, Paxinos G (2008) The mouse brain in stereotaxic coordinates. Academic Press, New York"},{"key":"6525_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.bmcl.2007.12.028","volume":"18","author":"AK Ghosh","year":"2008","unstructured":"Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Xu X, Miller HB, Reddy DS, Weerasena V, Turner R, Chang W, Koelsch G, Tang J (2008) Potent memapsin 2 (\u03b2-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 18:1031\u20131036","journal-title":"Bioorg Med Chem Lett"},{"key":"6525_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid \u03b2-peptide. Nat Rev Mol Cell Biol 8:101\u2013112","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6525_CR23","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26:5481\u20135503","journal-title":"Mol Psychiatry"},{"key":"6525_CR24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","volume":"28","author":"BP Imbimbo","year":"2019","unstructured":"Imbimbo BP, Watling M (2019) Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs 28:967\u2013975","journal-title":"Expert Opin Investig Drugs"},{"key":"6525_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejphar.2017.02.001","volume":"798","author":"K Ito","year":"2017","unstructured":"Ito K, Tatebe T, Suzuki K, Hirayama T, Hayakawa M, Kubo H, Tomita T, Makino M (2017) Memantine reduces the production of amyloid-\u03b2 peptides through modulation of amyloid precursor protein trafficking. Eur J Pharmacol 798:16\u201325","journal-title":"Eur J Pharmacol"},{"key":"6525_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K (2012) A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature 488:96\u201399","journal-title":"Nature"},{"key":"6525_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.nbd.2008.10.006","volume":"33","author":"R Kimura","year":"2009","unstructured":"Kimura R, Ohno M (2009) Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 33:229\u2013235","journal-title":"Neurobiol Dis"},{"key":"6525_CR28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1471-4159.2010.06608.x","volume":"113","author":"R Kimura","year":"2010","unstructured":"Kimura R, Devi L, Ohno M (2010) Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer\u2019s disease transgenic mice. J Neurochem 113:248\u2013261","journal-title":"J Neurochem"},{"key":"6525_CR29","doi-asserted-by":"publisher","first-page":"11693","DOI":"10.1523\/JNEUROSCI.2766-05.2005","volume":"25","author":"FM Laird","year":"2005","unstructured":"Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-\u03b2 amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25:11693\u201311709","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"6525_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1471-4159.2011.07478.x","volume":"120","author":"ME Larson","year":"2012","unstructured":"Larson ME, Lesn\u00e9 SE (2012) Soluble A\u03b2 oligomer production and toxicity. J Neurochem 120(Suppl 1):125\u2013139","journal-title":"J Neurochem"},{"key":"6525_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ana.24969","volume":"82","author":"H Martiskainen","year":"2017","unstructured":"Martiskainen H, Herukka SK, Stan\u010d\u00e1kov\u00e1 A, Paananen J, Soininen H, Kuusisto J, Laakso M, Hiltunen M (2017) Decreased plasma \u03b2-amyloid in the Alzheimer\u2019s disease APP A673T variant carriers. Ann Neurol 82:128\u2013132","journal-title":"Ann Neurol"},{"key":"6525_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","volume":"17","author":"E McDade","year":"2021","unstructured":"McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B, Haass C, Reiman EM, Sperling R, Tariot PN, Yan R, Masters CL, Vassar R, Lichtenthaler SF (2021) The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol 17:703\u2013714","journal-title":"Nat Rev Neurol"},{"key":"6525_CR33","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129\u201310140","journal-title":"J Neurosci"},{"key":"6525_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.brainresbull.2016.04.007","volume":"126","author":"M Ohno","year":"2016","unstructured":"Ohno M (2016) Alzheimer\u2019s therapy targeting the \u03b2-secretase enzyme BACE1: benefits and potential limitations from the perspective of animal model studies. Brain Res Bull 126:183\u2013198","journal-title":"Brain Res Bull"},{"key":"6525_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/npr2.12174","volume":"41","author":"M Ohno","year":"2021","unstructured":"Ohno M (2021) Accelerated long-term forgetting is a BACE1 inhibitor-reversible incipient cognitive phenotype in Alzheimer\u2019s disease model mice. Neuropsychopharmacol Rep 41:255\u2013259","journal-title":"Neuropsychopharmacol Rep"},{"key":"6525_CR36","doi-asserted-by":"publisher","first-page":"1161875","DOI":"10.3389\/frdem.2023.1161875","volume":"2","author":"M Ohno","year":"2023","unstructured":"Ohno M (2023) Accelerated long-term forgetting: a sensitive paradigm for detecting subtle cognitive impairment and evaluating BACE1 inhibitor efficacy in preclinical Alzheimer\u2019s disease. Front Dement 2:1161875","journal-title":"Front Dement"},{"key":"6525_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0896-6273(03)00810-9","volume":"41","author":"M Ohno","year":"2004","unstructured":"Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer\u2019s disease. Neuron 41:27\u201333","journal-title":"Neuron"},{"key":"6525_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1460-9568.2005.04551.x","volume":"23","author":"M Ohno","year":"2006","unstructured":"Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF (2006) Temporal memory deficits in Alzheimer\u2019s mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci 23:251\u2013260","journal-title":"Eur J Neurosci"},{"key":"6525_CR39","doi-asserted-by":"publisher","first-page":"eaao5620","DOI":"10.1126\/scitranslmed.aao5620","volume":"10","author":"MH Ou-Yang","year":"2018","unstructured":"Ou-Yang MH, Kurz JE, Nomura T, Popovic J, Rajapaksha TW, Dong H, Contractor A, Chetkovich DM, Tourtellotte WG, Vassar R (2018) Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Sci Transl Med 10:eaao5620","journal-title":"Sci Transl Med"},{"key":"6525_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","volume":"82","author":"MP Parsons","year":"2014","unstructured":"Parsons MP, Raymond LA (2014) Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82:279\u2013293","journal-title":"Neuron"},{"key":"6525_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00401-017-1804-9","volume":"135","author":"F Peters","year":"2018","unstructured":"Peters F, Salihoglu H, Rodrigues E, Herzog E, Blume T, Filser S, Dorostkar M, Shimshek DR, Brose N, Neumann U, Herms J (2018) BACE1 inhibition more effectively suppresses initiation than progression of \u03b2-amyloid pathology. Acta Neuropathol 135:695\u2013710","journal-title":"Acta Neuropathol"},{"key":"6525_CR42","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.3390\/ijms241512283","volume":"24","author":"K Pratsch","year":"2023","unstructured":"Pratsch K, Unemura C, Ito M, Lichtenthaler SF, Horiguchi N, Herms J (2023) New highly selective BACE1 inhibitors and their effects on dendritic spine density in vivo. Int J Mol Sci 24:12283","journal-title":"Int J Mol Sci"},{"key":"6525_CR43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s43587-023-00410-4","volume":"3","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Aisen PS (2023) Detection and treatment of Alzheimer\u2019s disease in its preclinical stage. Nat Aging 3:520\u2013531","journal-title":"Nat Aging"},{"key":"6525_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2009.11.016","volume":"470","author":"B Ray","year":"2010","unstructured":"Ray B, Banerjee PK, Greig NH, Lahiri DK (2010) Memantine treatment decreases levels of secreted Alzheimer\u2019s amyloid precursor protein (APP) and amyloid beta (A\u03b2) peptide in the human neuroblastoma cells. Neurosci Lett 470:1\u20135","journal-title":"Neurosci Lett"},{"key":"6525_CR45","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archneurol.2011.69","volume":"68","author":"LS Schneider","year":"2011","unstructured":"Schneider LS, Dagerman KS, Higgins JP, McShane R (2011) Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 68:991\u2013998","journal-title":"Arch Neurol"},{"key":"6525_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-9-48","volume":"9","author":"S Tu","year":"2014","unstructured":"Tu S, Okamoto S, Lipton SA, Xu H (2014) Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease. Mol Neurodegener 9:48","journal-title":"Mol Neurodegener"},{"key":"6525_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00213-004-2132-z","volume":"180","author":"D Van Dam","year":"2005","unstructured":"Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP (2005) Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology 180:177\u2013190","journal-title":"Psychopharmacology"},{"key":"6525_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/NDT.S4048","volume":"5","author":"RJ van Marum","year":"2009","unstructured":"van Marum RJ (2009) Update on the use of memantine in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat 5:237\u2013247","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6525_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321","journal-title":"N Engl J Med"},{"key":"6525_CR50","first-page":"78","volume":"6","author":"R Vassar","year":"2019","unstructured":"Vassar R (2019) Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus: implications for BACE1 inhibitor clinical trials. J Prev Alzheimers Dis 6:78\u201384","journal-title":"J Prev Alzheimers Dis"},{"key":"6525_CR51","doi-asserted-by":"crossref","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group (2013) Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol 12:357\u2013367","DOI":"10.1016\/S1474-4422(13)70044-9"},{"key":"6525_CR52","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-023-00636-1","volume":"18","author":"SP Yu","year":"2023","unstructured":"Yu SP, Jiang MQ, Shim SS, Pourkhodadad S, Wei L (2023) Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer\u2019s disease. Mol Neurodegener 18:43","journal-title":"Mol Neurodegener"},{"key":"6525_CR53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.biopsych.2018.04.022","volume":"84","author":"K Zhu","year":"2018","unstructured":"Zhu K, Peters F, Filser S, Herms J (2018a) Consequences of pharmacological BACE inhibition on synaptic structure and function. Biol Psychiatry 84:478\u2013487","journal-title":"Biol Psychiatry"},{"key":"6525_CR54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.biopsych.2016.12.023","volume":"83","author":"K Zhu","year":"2018","unstructured":"Zhu K, Xiang X, Filser S, Marinkovi\u0107 P, Dorostkar MM, Crux S, Neumann U, Shimshek DR, Rammes G, Haass C, Lichtenthaler SF, Gunnersen JM, Herms J (2018b) Beta-site amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6. Biol Psychiatry 83:428\u2013437","journal-title":"Biol Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06525-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06525-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06525-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T19:03:12Z","timestamp":1713553392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06525-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6525"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06525-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"type":"print","value":"0033-3158"},{"type":"electronic","value":"1432-2072"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"14 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}